stonks4u
Sign up free
GH logo

GH Guardant Health, Inc.

NASDAQ Global Select · Medical - Diagnostics & Research · Healthcare

$157.21
-2.33 (-1.46%)

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (ava…

Market Cap: $21.10Bguardanthealth.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

50
5088126164
Aug 11Aug 14

Quote

Day Range
$156.21 – $159.54
52-Week Range
$53.40 – $176.58
Volume
$2.47M
Market Cap
$21.10B
50-Day Avg
$149.58
200-Day Avg
$112.03
Prev Close
$159.54
Open
$158.00

Valuation & Ratios

P/E Ratio
-30.77
EPS
$-3.32
P/B Ratio
-128.95
P/S Ratio
13.04
Debt/Equity
-17.22
Current Ratio
4.84
Dividend Yield
+0.0%
Gross Margin
+64.5%

Returns & Efficiency

Return on Equity
+419.2%
Return on Assets
-20.7%
FCF Yield
-1.8%
EV/EBITDA
-37.81

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$982.02M$-416.28M$-3.32
2024$739.02M$-436.37M$-3.56
2023$563.95M$-479.45M$-4.28
2022$449.54M$-654.59M$-6.41
2021$373.65M$-405.67M$-4.00

Social Signal Score

64
5d
65
5 mentions
—
30d
64
5 mentions
—
60d
64
5 mentions
—
90d
64
5 mentions
—
news: 3 · marketaux: 1 · rss: 1

Earnings

Wed, Oct 28(in 2 months)

Consensus estimate $-0.28 per share

4of 7 quarters beat consensus

Typical surprise +15.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Jul 30$-0.90 vs $-0.76miss
  • Thu, May 7$-0.85 vs $-0.81miss
  • Thu, Feb 19$-0.90 vs $-0.77miss
  • Wed, Oct 29$-0.39 vs $-0.48beat
  • Wed, Jul 30$-0.44 vs $-0.52beat
  • Wed, Apr 30$-0.49 vs $-0.61beat

Estimates and results for GH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

GHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (5)

  • Newsmarketbeat.com·1d ago·Neutral

    Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.

    View source ↗
  • News (RSS)seekingalpha·2d ago·Positive

    Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

    View source ↗
  • Newsseekingalpha.com·2d ago·Positive

    Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

    View source ↗
  • News (Marketaux)finance.yahoo.com·3d ago·Neutral

    Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million Guardant Health serves[+242 characters]

    View source ↗
  • Newsseekingalpha.com·3d ago·Positive

    Guardant Health: Screening And MRD Are Just Getting Started Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.

    View source ↗